NuCana (NCNA) Common Equity (2015 - 2025)
NuCana (NCNA) reported Common Equity of $32.4 million for Q4 2025, up 323.44% on a YoY basis from $7.6 million in Q4 2024, and down 7.5% sequentially from $35.0 million in Q3 2025.
NuCana (NCNA) Common Equity (2015 - 2025) Analysis & Trends
NuCana (NCNA) has 11 years of Common Equity data on file, last reported at $32.4 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity rose 323.44% year-over-year to $32.4 million; the trailing twelve-month figure through Dec 2025 stood at $32.4 million (up 323.44% YoY), and the FY2025 full-year result was $32.1 million, up 321.44% from the prior year.
- Common Equity slipped to $32.4 million in Q4 2025, from $35.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $126.1 million in Q1 2021 to a low of $4.8 million in Q2 2024.
- A 5-year average of $46.4 million and a median of $34.6 million in 2023 frame the typical range for Common Equity.
- Across the five-year window, Common Equity plunged 86.0% in 2024 and soared 519.25% in 2025, its largest moves.
- Tracing NCNA's Common Equity over 5 years: stood at $88.4 million in 2021, then sank by 48.89% to $45.2 million in 2022, then plunged by 59.09% to $18.5 million in 2023, then tumbled by 58.64% to $7.6 million in 2024, then surged by 323.44% to $32.4 million in 2025.
- Business Quant data shows NCNA's Common Equity at $32.4 million in Q4 2025, $35.0 million in Q3 2025, and $9.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.36 Mn |
| Sep 30, 2025 | 34.98 Mn |
| Jun 30, 2025 | 9.85 Mn |
| Mar 31, 2025 | 5.26 Mn |
| Dec 31, 2024 | 7.64 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 4.80 Mn |
| Mar 31, 2024 | 12.85 Mn |
| Dec 31, 2023 | 18.48 Mn |
| Sep 30, 2023 | 27.58 Mn |
| Jun 30, 2023 | 34.26 Mn |
| Mar 31, 2023 | 38.59 Mn |
| Dec 31, 2022 | 45.16 Mn |
| Sep 30, 2022 | 62.10 Mn |
| Jun 30, 2022 | 70.57 Mn |
| Mar 31, 2022 | 78.79 Mn |
| Dec 31, 2021 | 88.36 Mn |
| Sep 30, 2021 | 106.77 Mn |
| Jun 30, 2021 | 117.68 Mn |
| Mar 31, 2021 | 126.11 Mn |